Beacon Financial Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.73M Buy
10,847
+233
+2% +$50.1K 0.25% 95
2026
Q1
$2.31M Buy
10,614
+3
+0% +$665 0.23% 105
2025
Q4
$2.42M Buy
10,611
+107
+1% +$24.4K 0.24% 98
2025
Q3
$2.43M Buy
10,504
+127
+1% +$25.9K 0.24% 102
2025
Q2
$1.93M Buy
10,377
+140
+1% +$26K 0.2% 115
2025
Q1
$2.14M Sell
10,237
-756
-7% -$147K 0.23% 101
2024
Q4
$1.95M Sell
10,993
-24
-0.2% -$4.41K 0.21% 108
2024
Q3
$2.18M Sell
11,017
-268
-2% -$50K 0.24% 98
2024
Q2
$1.94M Buy
11,285
+143
+1% +$23.7K 0.22% 112
2024
Q1
$2.03M Sell
11,142
-272
-2% -$46.9K 0.23% 104
2023
Q4
$1.77M Buy
11,414
+285
+3% +$41.5K 0.22% 111
2023
Q3
$1.64M Sell
11,129
-261
-2% -$38.3K 0.23% 101
2023
Q2
$1.52M Sell
11,390
-267
-2% -$39.2K 0.21% 107
2023
Q1
$1.88M Sell
11,657
-1,965
-14% -$300K 0.26% 95
2022
Q4
$2.2M Sell
13,622
-769
-5% -$118K 0.3% 88
2022
Q3
$2.05M Sell
14,391
-660
-4% -$94.7K 0.32% 83
2022
Q2
$2.29M Sell
15,051
-31
-0.2% -$4.74K 0.34% 84
2022
Q1
$2.47M Sell
15,082
-21
-0.1% -$3.05K 0.33% 82
2021
Q4
$2.04M Buy
15,103
+241
+2% +$28.5K 0.27% 88
2021
Q3
$1.62M Buy
14,862
+393
+3% +$44.9K 0.22% 100
2021
Q2
$1.68M Buy
14,469
+126
+0.9% +$14.2K 0.24% 99
2021
Q1
$1.61M Hold
14,343
0.25% 100
2020
Q4
$1.61M Sell
14,343
-1,214
-8% -$117K 0.25% 101
2020
Q3
$1.36M Buy
15,557
+447
+3% +$42.1K 0.24% 98
2020
Q2
$1.46M Buy
15,110
+181
+1% +$15.9K 0.28% 94
2020
Q1
$1.22M Buy
14,929
+5,253
+54% +$447K 0.27% 97
2019
Q4
$857K Sell
9,676
-488
-5% -$40.5K 0.11% 124
2019
Q3
$761K Buy
10,164
+149
+1% +$10.2K 0.13% 122
2019
Q2
$728K Buy
10,015
+1,918
+24% +$151K 0.12% 125
2019
Q1
$653 Buy
8,097
+638
+9% +$52.2K 0.11% 122
2018
Q4
$680K Buy
7,459
+30
+0.4% +$2.64K 0.13% 116
2018
Q3
$703K Sell
7,429
-1,222
-14% -$116K 0.12% 118
2018
Q2
$802K Buy
8,651
+26
+0.3% +$2.54K 0.14% 113
2018
Q1
$816K Sell
8,625
-870
-9% -$95.6K 0.14% 114
2017
Q4
$918K Sell
9,495
-3,285
-26% -$310K 0.16% 99
2017
Q3
$1.14M Buy
12,780
+253
+2% +$19.3K 0.21% 87
2017
Q2
$908K Sell
12,527
-76
-0.6% -$5.11K 0.17% 92
2017
Q1
$825K Buy
12,603
+3,816
+43% +$240K 0.16% 92
2016
Q4
$550K Buy
8,787
+952
+12% +$58.1K 0.11% 113
2016
Q3
$492K Buy
7,835
+611
+8% +$39.6K 0.1% 130
2016
Q2
$447K Sell
7,224
-5,641
-44% -$344K 0.1% 124
2016
Q1
$733K Buy
12,865
+1,856
+17% +$103K 0.16% 85
2015
Q4
$658K Buy
11,009
+259
+2% +$14.9K 0.15% 89
2015
Q3
$567K Sell
10,750
-5,568
-34% -$362K 0.14% 93
2015
Q2
$1.1M Buy
16,318
+1,091
+7% +$71.2K 0.24% 71
2015
Q1
$887K Buy
15,227
+2,817
+23% +$170K 0.2% 78
2014
Q4
$822K Buy
12,410
+2,422
+24% +$153K 0.17% 88
2014
Q3
$584K Sell
9,988
-1,806
-15% -$100K 0.13% 109
2014
Q2
$670K Buy
11,794
+5,039
+75% +$264K 0.15% 96
2014
Q1
$345K Buy
+6,755
New +$341K 0.07% 140

Other funds holding ABBV

Beacon Financial Group's ABBV Position: Q2 2026 in Review

Beacon Financial Group increased its AbbVie (ABBV) stake by 2.2% in Q2 2026, buying an estimated $50.1K and bringing the position to 10,847 shares worth $2.73M. The position accounts for 0.25% of the portfolio, ranked #95.

Beacon Financial Group first reported a position in ABBV in Q1 2014 and has held it in 50 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Beacon Financial Group held 10,847 shares of AbbVie worth $2.73M as of Q2 2026.
  • Beacon Financial Group bought 233 AbbVie shares in Q2 2026, an estimated $50.1K.
  • AbbVie made up 0.25% of Beacon Financial Group's portfolio in Q2 2026, its #95 holding.
  • Beacon Financial Group first reported a position in AbbVie in Q1 2014 and has held it in 50 quarters since.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Beacon Financial Group's 13F filing for Q2 2026, filed 16 Jul 2026.